KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). PMID 41576645 · Eur J Cancer · 2026-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial. PMID 40874769 · Clin Infect Dis · 2026-Feb-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ensemble Deep Learning-Based High-Precision Framework for Breast Cancer Detection from Histopathological Images. PMID 41827929 · Diagnostics (Basel) · 2026-Feb-24 The record describes a methodological study in deep learning for breast cancer diagnosis from images. It is not a randomized clinical trial, lacks a drug intervention, and does not report any time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol for the development and testing of a web-based patient decision aid for early-stage breast cancer patients within a cancer centre care: a mixed-method approach. PMID 41734922 · BMJ Open · 2026-Feb-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology. PMID 41730847 · Signal Transduct Target Ther · 2026-Feb-24 The record describes a secondary analysis of a randomized trial evaluating molecular profiling (including DNA and RNA profiling) for guiding cancer therapy, with overall survival (OS) as a time-to-event endpoint. However, the trial is described as a 'randomized study' (NCT02152254) without explicit mention of Phase III/IIIb or Phase II/III status, and the analysis focuses on concordance between profiling methods and correlates gene expression with OS, not the primary efficacy of a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Lay Health Worker-Led Symptom Intervention and Acute Care Use in Older Adults With Cancer: A Randomized Clinical Trial. PMID 41468027 · JAMA · 2026-Feb-24 While this is an original, randomized oncology trial in humans, it does not meet two key eligibility criteria: 1) It lacks a time-to-event primary/key secondary efficacy endpoint (OS, PFS, DFS, etc.), and 2) The intervention is non-drug (symptom assessment via health workers).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Conventional Versus Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumors ≤ 20 mm: Study Protocol for a Multicenter Randomized Controlled Trial (D-CURE Trial). PMID 41745223 · Methods Protoc · 2026-Feb-23 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Ultrasound-guided retro-superior costotransverse ligament space block (RSSB) versus subcostal transversus abdominis plane block (TAPB) for postoperative analgesia in gastric cancer patients undergoing laparoscopic gastrectomy : a prospective randomized controlled trial. PMID 41724933 · BMC Anesthesiol · 2026-Feb-23 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Progression-Free Survival versus Overall Survival in Patients with PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP versus Placebo. PMID 41756446 · Res Sq · 2026-Feb-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis. PMID 41722967 · Lancet · 2026-Feb-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial]. PMID 41975647 · Zhongguo Fei Ai Za Zhi · 2026-Feb-20 Record meets criteria for oncology, human, randomized trial with drug intervention and time-to-event efficacy endpoints (PFS, OS) as primary/secondary outcomes. However, metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. Without this confirmation, is_eligible must be false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. PMID 41499716 · J Clin Oncol · 2026-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Elderly Patients with Cancer Bone Metastases: A Target Trial Emulation Study. PMID 41752980 · Life (Basel) · 2026-Feb-17 The record describes a retrospective observational cohort study (target trial emulation) comparing denosumab to bisphosphonates. While it is an oncology study with a time-to-event endpoint and drug intervention, it does not meet the core eligibility requirement of being a randomized controlled trial (Phase III/IIIb or Phase II/III). The abstract explicitly states it is a retrospective cohort study, not a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. PMID 41707646 · Cell Rep Med · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Enhancing palliative care in intensive care units: protocol of EPIC, a controlled, cluster-randomised, non-blinded stepped-wedge design trial with crossover phase. PMID 41702660 · BMJ Open · 2026-Feb-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer. PMID 41537692 · Clin Cancer Res · 2026-Feb-17 The record is a secondary, biomarker-focused analysis (MRD) within a larger randomized trial (NADIM II). While it originates from a trial with oncology, human, randomized, drug intervention, and time-to-event components, this specific publication does not present the primary efficacy results of the parent trial. It is a secondary/prognostic analysis. The parent trial's phase is not explicitly confirmed in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial. PMID 41378996 · Clin Cancer Res · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. PMID 41378992 · Clin Cancer Res · 2026-Feb-17 The record describes a randomized, drug-intervention trial in human oncology with a time-to-event endpoint (PFS). However, two key criteria for eligibility cannot be definitively established from the provided metadata: 1) The formal trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the title, abstract, or metadata, though the title mentions 'late-phase' and the abstract notes it as a completed efficacy trial. 2) The report is a secondary/biomarker analysis ('exploratory analysis') of the GOG281/LOGS trial, not the primary formal-result report of the trial's main efficacy findings. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial. PMID 41335375 · Clin Cancer Res · 2026-Feb-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of Perioperative Supplementation with Arginine and Omega-3 on Postoperative Complications in Patients Undergoing Gastrointestinal Cancer Surgery: A Pilot Open-Label Randomized Controlled Trial. PMID 41754168 · Nutrients · 2026-Feb-16 The study is a randomized, open-label, pilot trial in oncology patients, but it is not a Phase III/IIIb or Phase II/III trial. The primary and secondary endpoints (postoperative complications, mortality at 1 month, length of stay) are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS). The intervention is nutritional supplementation, not a drug intervention. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Possible preventive effect of surgical glove compression therapy on oxaliplatin-induced peripheral neuropathy: study protocol of a multicentre, phase II/III, randomised controlled trial-the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)-12 trial. PMID 41698721 · BMJ Open · 2026-Feb-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Influence of gemcitabine combined with lobaplatin interventional embolization on vaginal flora and biofilm formation in patients with advanced cervical cancer. PMID 41697076 · Afr J Reprod Health · 2026-Feb-16 The study is an oncology randomized trial with a drug intervention, but the reported outcomes (vaginal flora changes, biofilm formation, and general 'curative effect') do not include a primary or key secondary time-to-event efficacy endpoint such as overall survival, progression-free survival, or Kaplan-Meier analysis. Therefore, it does not meet the eligibility criteria for the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial. PMID 41137194 · Int J Cancer · 2026-Feb-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. PMID 41689066 · Trials · 2026-Feb-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial. PMID 41692352 · Int J Radiat Oncol Biol Phys · 2026-Feb-13 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT. PMID 41836917 · Breast Care (Basel) · 2026-Feb-12 The record describes a retrospective subgroup analysis of the WSG-ADAPT-HR+/HER2- trial, which is not explicitly identified as a Phase III or Phase II/III trial for the drug intervention in question. The analysis integrates recurrence score and endocrine responsiveness to refine risk assessment, projecting theoretical benefit from other trials (NATALEE, monarchE) rather than reporting primary results of a randomized drug intervention comparison. While the parent trial may be randomized and involve drugs, this specific report is a secondary subgroup analysis, not a primary or definitive result report of the trial's drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of self-abdominal massage on gastrointestinal function in postoperative ileus: a randomised controlled trial protocol. PMID 41688115 · BMJ Open · 2026-Feb-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Fibrin sealant for prophylaxis of cervical anastomotic leakage after McKeown esophagectomy for esophageal or esophagogastric junction cancer (PLACE030): a Phase III multicenter randomized clinical trial. PMID 41677267 · Int J Surg · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium. PMID 41347825 · Blood · 2026-Feb-12 The record describes a secondary prognostic study on time-to-relapse in T-cell lymphoma, using data from cohorts that include a randomized trial, but it is not the original formal-result report of a Phase III or II/III randomized trial of a drug intervention. The trial phase is not explicitly confirmed as Phase III/II in the metadata or abstract, and the report type is a secondary analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia. PMID 41060318 · Blood · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. PMID 41672869 · Eur Urol · 2026-Feb-10 The record describes a multicenter randomized trial with a primary time-to-event endpoint (PSA-PFS) and drug intervention, meeting all eligibility criteria. The phase is explicitly stated as a randomized trial without a specific phase label, but given the definitive design (comparing established treatments), it qualifies as a Phase III/definitive trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A). PMID 41668051 · BMC Cancer · 2026-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
FLT3-ITD measurable residual disease from the QuANTUM-First trial. PMID 41052406 · Blood Adv · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Role of melatonin for prevention of necrotizing enterocolitis in preterm infants: a randomized controlled trial. PMID 41847903 · J Trop Pediatr · 2026-Feb-09 The study is a randomized controlled trial in humans with a drug intervention (melatonin) and reports original results, but it is not an oncology study. It focuses on a neonatal condition (necrotizing enterocolitis), which is outside the scope of the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial. PMID 41349543 · Cancer Cell · 2026-Feb-09 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L B
旧查询独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. PMID 41654611 · Sci Rep · 2026-Feb-07 The trial is explicitly described as a 'pilot study' and does not meet the phase requirement (Phase III/IIIb or Phase II/III). While it is randomized, has drug intervention, and reports time-to-event efficacy endpoints, the lack of definitive Phase II/III or Phase III evidence makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials. PMID 41651961 · Sci Rep · 2026-Feb-07 The record is a secondary analysis (journal article) of data from three separate Phase III trials, not the original formal report of a single randomized trial. It investigates associations between baseline cardiovascular medication use and outcomes, which is a post-hoc or secondary analysis, not the primary trial result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53). PMID 41796475 · Int J Gynecol Cancer · 2026-Feb-06 The record is a protocol for a planned randomized controlled trial comparing surgical techniques. It does not report results from a completed trial. Furthermore, the intervention is surgical, not drug-containing. The explicit trial phase is not stated in the provided metadata (though 'phase3_or_definitive' is null, the lack of explicit Phase III/IIIb designation and the absence of results are primary exclusions).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. PMID 41651834 · Nat Commun · 2026-Feb-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Does the Fissure Last Technique Really Reduce Postoperative Airleak After Lung Resection? Results From a Prospective Randomized Controlled Trial. PMID 41689184 · Interdiscip Cardiovasc Thorac Surg · 2026-Feb-05 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: results from the MAVERIC phase II trial. PMID 41572426 · Oncologist · 2026-Feb-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer. PMID 41537257 · Oncologist · 2026-Feb-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial. PMID 41520166 · Oncologist · 2026-Feb-05 The study is a Phase III randomized trial in oncology with a drug intervention, but its primary efficacy endpoint (complete response rate) is a binary outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the time-to-event criterion for inclusion in a Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Plant-based whole-food diets are feasible during autologous stem cell transplantation and are associated with dose-dependent microbiome modulation: Results from a pilot clinical trial. PMID 41674628 · medRxiv · 2026-Feb-04 The study is a single-arm, pilot trial in multiple myeloma patients, focusing on a dietary (plant-based food) intervention, not a drug. It lacks a randomized control arm, is not a Phase III/IIIb or Phase II/III trial, and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The primary endpoints are feasibility and tolerability, with secondary microbiome endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer. PMID 41174882 · Mol Ther · 2026-Feb-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo. PMID 41608890 · J Am Heart Assoc · 2026-Feb-03 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identifying Locally Recurrent Versus Second Primary Breast Cancer: Genomic Versus Clinical Criteria from Carolina Breast Cancer Study Phase III. PMID 41324404 · Cancer Epidemiol Biomarkers Prev · 2026-Feb-03 This is a genomic classification study from the Carolina Breast Cancer Study Phase III cohort. It is a human, oncology, Phase III study with original results, but it is not randomized, has no drug intervention, and its primary endpoints are diagnostic accuracy metrics for classifying tumor recurrence vs. second primary, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the inclusion criteria for a drug-containing, randomized, Phase III/IIIb or Phase II/III trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. PMID 41676981 · J Antimicrob Chemother · 2026-Feb-02 Study is a Phase IV randomized controlled trial of an antiretroviral regimen for HIV infection, not oncology. No primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) is reported. Primary outcome is 'treatment failure' defined by virological failure, discontinuation, or loss to follow-up, which is not a standard oncology time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Self-Acupressure for Fatigue in Patients Surviving Ovarian Cancer: A Randomized Clinical Trial. PMID 41642626 · JAMA Netw Open · 2026-Feb-02 Study is a randomized, phase 3 trial in human ovarian cancer survivors, but the intervention is self-acupressure (non-drug), and the primary efficacy endpoint is change in fatigue score (not a time-to-event endpoint like OS, PFS, DFS, etc.).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Fecal incontinence after prostate cancer irradiation: a systematic literature review. PMID 41629638 · Prostate Cancer Prostatic Dis · 2026-Feb-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -